Specifically, 10 potential therapeutic targets (AKT1, CASP3, IL6, JUN, MYC, MAPK3, SRC, STAT3, TNF, TP53) were directly linked to the KEGG pathway “hepatitis B” and were associated with 21 compounds (SQ7, ZJ11, ZJ3, ZJ4, CBM9, CF2, CF3, QYS8, QYS9, ZJ8, CL3, CL5, ZZS1, CL2, DSL4, ZJ10, ZJ6, DSL5, JTS1, TM12, XYS18; Table S2). The gene discussed is JUN; the disease is hepatitis B virus infection.